✦ LIBER ✦

Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer

✍ Scribed by Helga Bernhard; Julia Neudorfer; Kerstin Gebhard; Heinke Conrad; Christine Hermann; Jörg Nährig; Falko Fend; Wolfgang Weber; Dirk H. Busch; Christian Peschel

Publisher: Springer-Verlag
Year: 2007
Tongue: English
Weight: 498 KB
Volume: 57
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-007-0355-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Identification of HER2/neu-derived pepti

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes

✍ Koji Kono; Yang Rongcun; Jehad Charo; Fumiko Ichihara; Esteban Celis; Alessandro 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 127 KB 👁 2 views

We have derived HLA-A2.1-restricted, gastric cancerspecific cytotoxic T lymphocyte (CTL) lines by repetitive in vitro stimulation of tumor-associated lymphocytes (TAL) with autologous tumor cells. The HER2/neu specificity of these gastric cancer-specific CTLs was demonstrated using HER2/neu-transfec

EGF-R and Her2/neu overexpressing tumors

EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy

✍ Christine Solbach; Marc Roller; Kai Budischewski; Sibylle Loibl; Maria Nicoletti 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 156 KB

Evaluation of HER2 status: For the treat

Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)

✍ Shinobu Umemura; Goi Sakamoto; Hironobu Sasano; Hitoshi Tsuda; Futoshi Akiyama; 📂 Article 📅 2001 🏛 Springer Japan 🌐 English ⚖ 998 KB

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

Adoptive transfer of HER2/neu-specific T

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

✍ Johanna K. Morales; Maciej Kmieciak; Laura Graham; Marta Feldmesser; Harry D. Be 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 657 KB